Neuronetics Set to Join Russell 2000® Index
June 23 2021 - 4:29PM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, today announced that the company will
be added to the Russell 2000® Index at the conclusion of the 2021
Russell indexes annual reconstitution, effective after the US
market opens on June 28, according to a preliminary list of
additions posted June 4.
Annual Russell indexes reconstitution captures the 4,000 largest
US stocks as of May 7, ranking them by total market capitalization.
Membership in the US all-cap Russell 3000® Index, which remains in
place for one year, means automatic inclusion in the large-cap
Russell 1000® Index or small-cap Russell 2000® Index as well as the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
“We are very pleased to be included in the Russell 2000, which
we believe will increase our visibility within the investment
community,” said Keith Sullivan, President and Chief Executive
Officer of Neuronetics, Inc. “Our inclusion validates efforts to
create value for our stockholders while we execute our strategy to
bring the benefits of NeuroStar Advanced Therapy for Mental Health
to patients suffering from depression and other mental health
conditions.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.6 trillion in
assets are benchmarked against Russell’s US indexes. Russell
indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell 3000® Index and the Russell
indexes reconstitution, go to the “Russell Reconstitution” section
on the FTSE Russell website.
About Neuronetics
Neuronetics, Inc. is a commercial-stage medical technology
company focused on designing, developing, and marketing products
that improve the quality of life for patients who suffer from
psychiatric disorders. Its commercial product, the NeuroStar®
Advanced Therapy System, is a non-invasive and non-systemic
office-based treatment that uses transcranial magnetic stimulation,
or TMS, to create a pulsed, MRI-strength magnetic field that
induces electrical currents designed to stimulate specific areas of
the brain associated with mood. The system is cleared by the United
States Food and Drug Administration, or FDA, for the treatment of
major depressive disorder in adult patients who have failed to
achieve satisfactory improvement from prior antidepressant
medication in the current episode. NeuroStar is also available in
other parts of the world, including Japan, where it is listed under
Japan’s national health insurance. Additional information can be
found at www.neuronetics.com.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 70 countries,
covering 98% of the investable market globally. FTSE Russell index
expertise and products are used extensively by institutional and
retail investors globally. Approximately $17.9 trillion is
currently benchmarked to FTSE Russell indexes. For over 30 years,
leading asset owners, asset managers, ETF providers and investment
banks have chosen FTSE Russell indexes to benchmark their
investment performance and create ETFs, structured products and
index-based derivatives. A core set of universal principles guides
FTSE Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on applying the highest
industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation
and customer partnerships as it seeks to enhance the breadth, depth
and reach of its offering. FTSE Russell is wholly owned by London
Stock Exchange Group. For more information, visit
www.ftserussell.com.
Investor Contact:Mike Vallie or Mark KlausnerWestwicke
Partners443-213-0499ir@neuronetics.comMedia
Contact:Chelsey MankoVault
Communications610-455-2778cmanko@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2024 to May 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From May 2023 to May 2024